1. Robinson RG, McHugh PR,Folstein MF. Measurement of appetite distrubances in psychiatric disorders. J Psychiatr Res 1975; 12: 59-68.
2. Paykel ES. Depression and appetite. J Psychosom Res 1977; 21: 401-407.
3. Mezzich JE, Raab JS. Depressive symptomology across the Americas. Arch Gen Psychiatry 1980; 37: 818-823.
4. Stunkard AJ, Fernstrom MH, Price A, Frank E, Kupfer DJ. Direction of weight change in recurrent depression: A possible marker for subtypes of depression. Arch Gen Psychiatry 1990; 47: 857-860.
5. Weissenburger JA, Rush AJ, Giles DE, Stunkard AJ. Weight change in depression. Psychiatry Res 1986; 17: 275-283.
6. Rudorfer MV, Manji HK, Potter WZ. Comparative tolera-bility profiles of the newer versus older antidepressants. Drug Saf 1994; 10:18-46.
7. Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 1992; 43 (Suppl. 2): 11-23.
8. Paykel ES, Meuller PS, DeLa Vergne PM. Amitriptyline, weight gain, and carbohydrate craving. Br J Psychiatry 1973; 123: 501-507.
9. Kupfer DJ, Coble PA, Rubenstein D. Changes in weight during treatment for depression. Psychosom Med 1979; 41: 535-543.
10. Harris B, Young J, Hughes B. Appetite and weight duirng short-term antidepressant treament. Br J Psychiatry 1986; 145: 645-648.
11. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: A comparison study of four medications. Psychiatry Res 1988; 26: 265-271.
12. Berken GH, Weinstein D, Stern WC. Weight gain: A side effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133-138.
13. Fernstrom MH, Kupfer DJ. Imipramine treatment and preference for sweets. Appetite 1988; 10:149-155.
14. Fernstrom MH, Krowinski RL, Kupfer DJ. Appetite and food preference in depression: Effects of imipramine treatment. Biol Psychiatry 1987; 22: 529-539.
15. Drewnowski A, Greenwood MRC. Cream and sugar: Human preferences for high-fat foods. Physiol Behav 1982; 30: 629—633.
16. Garrow JS. Energy Balance and Obesity in Man, 2nd edn. Oxford: Elsevier-North Holland Press, 1978.
17. Fernstrom MH, Spiker DG, Epstein LH, Kupfer DJ. Resting metabolic rate is reduced in patients treated with antidepressants. Biol Psychiatry 1985; 20: 688—692.
18. Fernstrom MH. Drugs that cause weight gain. Obes Res 1995; 3(Suppl 4): 435—439.
19. Fogelson DL. Weight gain during fluoxetine treatment. J Clin Psychopharmacol 1991; 11: 220—221.
20. Sussman N, Ginsburg DL. Weight gain associated with SSRIs. Primary Psychiatry 1988; 5: 28—37.
21. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1991; 56: 288—296.
22. Bouver CB, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996; 11: 273—276.
23. Palvimaki EP, Roth BL, Majasuo H, et al. Interactions of selective serotonin receptor inhibitors with the serotonin 5HT2C receptor. Psychopharmacology 1996; 126: 234— 240.
24. Laakso A, Palvimaki EP, Kuoppamaki M, et al. Chronic citalopram and fluoxetine treatments upregulate 5-HT2C receptors in the rat choroid plexus. Neuropsy-chophar-macology 1996; 15: 143—151.
25. Ackerman S and Nolan LJ. Bodyweight gain induced by psychotropic drugs: incidence, mechanisms, and management. CNS Drugs 1998; 9: 135—151.
26. John RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993—1000.
27. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: mechanism and management. Drug Saf 1996; 14: 329—342.
28. Holt RA, Maunder EMW. Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy? J Nutr Hum Diet 1996; 9: 127—133.
29. Mefferd RB, Labrosse EH, Gawienowski AM, Williams R. Influence of chlorpromazine on certain biochemical variables of chornic male schizophrenics. J Nerv Ment Dis 1958; 127: 167—179.
30. Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959; 20: 53—57.
31. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214—217.
32. Bernstein JG. Induction of obesity by psychotropic drugs. Ann NY Acad Med 1988; 499: 203—215.
33. Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989; 82: 611—617.
34. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463—472.
35. Klett CJ, Caffey EM. Weight changes during treatment with phenothizaine derivatives. J Neuropsychiatry 1960; 2: 102—108.
36. Holden JMC, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psycho-
somatics 1970; 11: 551-561.
37. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60: (S2)20-24.
38. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979; 59: 525-528.
39. Cookson JC, Kennedy NM, Gribbon D. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol 1986; S1: 41-51.
40. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1982; 149: 68-72.
41. Sachs GS, Guille C. Weight gain associated with the use of psychotropic medications. J Clin Psychiatry 1999; 60(S2): 16-19.
42. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314.
43. Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80.
44. Wirshing DA, Wirshing WC, Kysar L, et al. Novel anti-psychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363.
45. Breum L, Astrup AV, Quaade F. Increased appetite after prenatal haloperidol exposure—a case report. Int J Obes 1993; 10: 609.
46. Convanis A, Gupta K, Jeavons PM. Sodium valproate: Monotherapy and polytherapy. Epilepsia 1982; 23: 693-720.
47. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240-244.
48. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-69.
49. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283: 557- 581.
50. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999; 14: 490-495.
51. Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with car-bamazepine or valproate. Acta Neurol Scand 1983: 67: 235-241.
52. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, Werdelin L, Madsen J. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992; 41: 666-670.
53. Laub MC, Paetzke-Brunner, Jaeger G: Serum carnitine dyring valproic acid therapy: Epilepsia 1986; 27: 559-562.
54. Editorial. Carnitine deficiency. Lancet 1990; 631-633.
55. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-232.
56. Horton R, Rothwell NJ, Stock MJ. Chronic inhibition of
Gaba Transaminase results in activation of thermogenesis and brown fat in the rat. Gen Pharmacol 1988; 19: 403-405.
57. Coscina DV, Nobrega JN. Anorectic potency of inhibiting GABA transaminase in brain studies of hypothalamic, dietary and genetic obesities. Int J Obes 1984; 8: 191-200.
58. Wolden-Hanson T, Gidal BE, Atkinson RL. Evaluation of a rat model of valproate-induced obesity. Pharmacotherapy 1998; 18: 1075-1081.
59. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-771.
60. Lampl Y, Eshel Y, Rapaport A, Sarova-Pinhas I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14: 251-255.
61. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Mono-therapy Study Group. Lancet 1999; 354: 13-19.
62. Rahminiwati M, Nishimura M. Diazepam-induced hyper-phagia in mice is sensitive to quinpirole. J Vet Med Sci 1999; 61: 777-780.
63. Cooper SJ. GABA and endorphin mechanism in relation to the effects of benzodiazepines on feeding and drinking. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 495-505.
64. Jing X, Wala EP, Sloan JW. The effect of chronic ben-zodiazepines exposure on body weight in rats. Pharmacol Res 1998; 37:179-189.
65. Frisbie JH, Aguilera EJ. Diazepam and body weight in myelopathy patients. J Spinal Cord Med 1995; 18: 200-202.
66. Jokinen K, Koskinen T, Selonen R. Flupenthixol versus diazepam in the treatment of psychosomatic disorders: a double-blind, multi-centre trial in general practice. Phar-matherapeutica 1984; 3: 573-581.
67. Bjertnaes A, Block JM, Hafstad PE, Holte M, Ottemo I, Larsen T, Pinder RM, Steffensen K, Stulemeijer SM. A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. Acta Psychiatr Scand 1982; 66: 199-207.
68. Ostwald I, Adam K. Benzodiazepines cause small loss of body weight. BMJ 1980; 281:1039-1040.
69. Louis P, Spierings EL. Comparison of flunarizine (Sibelium) and pizotifen (Sanomigran) in migraine treatment: a double-blind study. Cephalalgia 1982; 2:197-203.
70. Toth K, Szonyi A. The appetite stimulating and weight gain promoting effect of peritol (cyproheptadine) examined on a great number of outpatients. Ther Hung 1976; 1: 24-32.
71. Walsh BT, Devlin MJ. The pharmacologic treatment of eating disorders. Psychiatr Clin North Am 1992; 15: 149-160.
72. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition 1996; 12(S1): S43-47.
73. Chervinsky P, Georgitis J, Banov C, Boggs P, Vande Souwe R, Greenstein S. Once daily loratadine versus as-temizole once daily. Ann Allergy 1994; 73:109-113.
74. Martinez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia 1988; 8(S8): 15-20.
75. Sorensen PS, Larsen BH, Rasmussen MJ, Kinge E, Iversen H, Alslev T, Nohr P, Pedersen KK, Schroder P, Lademann A, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 31: 650-657.
76. Centonze V, Magrone D, Vino M, Caporaletti P, Attolini E, Campanale G, Albano O. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5mg and 10 mg dose levels. Cephalalgia 1990; 10:17-24.
77. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902-903.
78. Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. S Afr Med J 1990; 77: 75-77.
79. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
81. Lithell HO. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press 1998; S3: 28-31.
82. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
83. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
84. DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988; 11: 567-573.
85. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280:140-146.
86. Carlson MG, Campbell PJ: Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42:1700-1707.
87. Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, Atchison JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Martul P, Matsuura N, Schoenle EJ, Sovik O, Swift PG, Tsou RM, Vanelli M, Aman J. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Diabet Med 1998; 15: 752-759.
88. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997; 350:1505-1510.
89. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
90. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
91. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24: 433-436.
92. Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 1998; 58: 345-349.
93. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas 1999; 32: 147-153.
94. Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception 1992; 46: 19-27.
95. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde B, Richelsen L. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 1999; 163: 55-62.
96. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, De Simone L, Orlandi R, Genazzani AR. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997; 82: 414-417.
97. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66:1279-1282.
98. Alexieva-Figusch J, van Gilse HA, Hop WC, Phoa CH, Blonk-van der Wijst J, Treurniet RE. Progestin therapy in advanced breast cancer: megestrol acetate—an evaluation of 160 treated cases. Cancer 1980; 46: 2369-2372.
99. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer—effect of tamoxifen. Breast Cancer Res Treat 1992; 22:129-132.
100. Goodwin PJ, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer—a descriptive study. Breast Cancer Res Treat 1988; 11: 59-66.
101. Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 1999; 17: 120-129.
102. Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, Lyman GH. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?. Breast Cancer Res Treat 1997; 44: 135-143.
103. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 1993; 11:1418-1429.
104. Kyle V, Hazleman BL. Treatment of polymyalgia rheu-matica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-666.
105. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zet-terman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver
Transpl Surg 1998; 4: 285-296.
106. Prummel MF, Mounts MP, Blank L, Berghout A, Koor-nneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342: 949-954.
107. Curtis JJ, Galla JH, Woodford SY, Saykaly RJ, Luke RG. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981; 1:166-171.
108. Horber FF, Zurcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986; 43: 758-769.
109. Zakrzewska KE, Cusin I, Stricker-Krongrad A, Boss O, Ricquier D, Jeanrenaud B, Rohner-Jeanrenaud F. Induction of obesity and hyperleptinemia by central glucocor-ticoid infusion in the rat. Diabetes 1999; 48: 365-370.
110. Zakrzewska KE, Sainsbury A, Cusin I, Rouru J, Jeanrenaud B, Rohner-Jeanrenaud F. Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids. Endocrinology 1999; 140: 3183-3187.
111. Chong PK, Jung RT, Scrimgeour CM, Rennie MJ. The effect of pharmacological dosages of glucocorticoids on free living total energy expenditure in man. Clin Endo-crinol (Oxf) 1994; 40: 577-581.
112. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996; 271: E317-325.
113. Tataranni PA, Pratley R, Maffei M, Ravussin E. Acute and prolonged administration of glucocorticoids (methylpred-nisolone) does not affect plasma leptin concentration in humans. Int J Obes Relat Metab Disord 1997; 21: 327-330.
International Textbook of Obesity. Edited by Per Bjorntorp.
Copyright © 2001 John Wiley & Sons Ltd Print ISBNs: 0-471-988707 (Hardback); 0-470-846739 (Electronic)
Was this article helpful?
Are you fed up with your frequent headache pain? 101 Simple Ways to Attack Your Headache BEFORE the Pain Starts Guaranteed No Pain, No Fear, Full Control Normal Life Again Headaches can stop you from doing all the things you love. Seeing friends, playing with the kids... even trying to watch your favorite television shows.